CapVest recapitalizes Curium in circa $7 billion deal to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
Client: CapVest Partners LLP (CapVest)
Client Location: United Kingdom
Target: Curium
Target Location: United States
The Transaction: Curium, a leading producer of radiopharmaceuticals, and CapVest Partners LLP (CapVest), a global investment firm, have announced the recapitalization of Curium via a new continuation vehicle (CV). The CV values Curium at circa $7 billion, representing the largest transaction in nuclear medicine globally.
Target Description: Over the last decade, Curium has positioned itself as a global leader in nuclear medicine. Its vertically integrated, global supply chain reliably delivers diagnostic and therapeutic radiopharmaceuticals to more than 14 million patients in 70+ countries across 6 continents every year. Curium boasts a broad portfolio of diagnostic radiopharmaceuticals and has an exciting, late-stage pipeline of Radioligand Therapies (RLTs) targeting neuroendocrine and prostate cancers, the two largest indications in nuclear medicine.
Meet our Senior Team
I cultivate enduring partnerships with clients by adopting a forward-thinking strategy, ensuring a foundation built on trust and proactive engagement.
Dr. Simon von Witzleben
Managing Director & Head of Transaction Opinions, Europe
London
View More Transactions in Transactions, Opinions & Board Advisory
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.